Small study checks COVID-19 vaccine power in young cancer patients

NCT ID NCT05164016

Knowledge-focused Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how well COVID-19 vaccines trigger an immune response in children and young adults (under 24) with cancer or who had a transplant or cellular therapy. Researchers measured antibody and T-cell levels after vaccination. The goal was to learn more about vaccine effectiveness in these vulnerable groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: COVID-19 vaccine
What this could lead to: If successful, this could help doctors understand how well COVID-19 vaccines protect immunocompromised patients and guide future vaccination strategies.
What could go wrong: This is a small, completed observational study with only 21 participants, so results may not apply to larger or different groups. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

21 people

The number who actually took part.

Started

Jun 2022

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Those who meet the Eligibility Criteria.

Ages

Up to 24 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient receiving care at St. Jude Children's Hospital or Le Bonheur Children's Hospital * Less than 24 years old at the time of enrollment (Day 0) * Planning to receive a COVID-19 vaccine as part of clinical care * Patient is one of the following: 1. Diagnosed with a Hematological Malignancy (Group A), or 2. Received a hematopoietic cell transplant or cellular therapy (Group B), or 3. Diagnosed with a solid tumor malignancy (Group C). 4. Received a solid organ transplant (Group D), or 5. Does not have cancer and has not received any type of transplant (Group E) * Willing and able to provide informed consent Exclusion Criteria: * Received a COVID-19 vaccine prior to enrollment (Day 0).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer disease related to transplantation hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Cellular therapy Hematologic malignancy Hematopoietic cell transplant Hematopoietic system--cancer Solid organ transplant Solid tumor malignancy Transplant-related cancer

Small study checks COVID-19 vaccine power in young cancer patients

What the study statuses mean